北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
The properties of tumor-initiating cells from a hepatocellular carcinoma patient′s primary and recurrent tumor
作者: Xu, Xiao-Lan1,2; Xing, Bao-Cai3; Han, Hai-Bo1; Zhao, Wei1; Hu, Mei-Hao2; Xu, Zuo-Liang1; Li, Ji-You4; Xie, Yong5; Gu, Jun2; Wang, Yu1; Zhang, Zhi-Qian1
刊名: CARCINOGENESIS
发表日期: 2010-02-01
DOI: 10.1093/carcin/bgp232
卷: 31, 期:2, 页:167-174
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: CANCER STEM-CELLS ; B-VIRUS DNA ; POLY(ADP-RIBOSE) POLYMERASE ; LIVER-CANCER ; ALDEHYDE DEHYDROGENASE ; STEM/PROGENITOR CELLS ; GENE-EXPRESSION ; SIDE POPULATION ; INHIBITORS ; TUMORIGENICITY
英文摘要:

Hepatocellular carcinoma (HCC) is associated with a high morbidity and mortality due to its high rate of recurrence. However, little is known about the biological characteristics of recurrent HCC cells. A single patient′s primary and recurrent HCC-derived cell lines, Hep-11 and Hep-12, respectively, were established by primary culture. These two cell lines have the same hepatitis B virus integration site and share many common amplifications and deletions, which suggest that they have the same clonal origin. While Hep-11 cells were non-tumorigenic at 16 weeks following injection of up to 10 000 cells, injection of only 100 Hep-12 cells was sufficient to initiate tumor growth, and all single Hep-12 clones were tumorigenic in immunodeficient mice. Compared with Hep-11, Hep-12 cells expressed the oval cell markers AFP, NCAM/CD56, c-kit/CD117, as well as multiple stem cell markers such as Nanog, OCT4 and SOX2. In addition, > 90% of Hep-12 cells were aldehyde dehydrogenase positive. They were also less resistant to paclitaxel, but more resistant to doxorubicin, cisplatin and hydroxycamptothecin (HCPT), which had been administrated to the patient. Furthermore, Hep-12 cells expressed higher levels of poly (adenosine diphosphate-ribose) polymerase-1 (PARP-1) than Hep-11, and PARP-1 inhibition potentiated the sensitivity to HCPT in Hep-12 cells but not in Hep-11 cells. These results indicate that a large population of the recurrent HCC-derived Hep-12 cells were tumor-initiating cells and that elevated expression of PARP-1 was related to their resistance to HCPT.

语种: 英语
所属项目编号: 30670413 ; 30671060 ; 2010CB529402 ; NCET-07-0031
项目资助者: National Natural Science Foundation of China ; National Basic Research Program of China ; Program for New Century Excellent Talents in University of China
WOS记录号: WOS:000274088300004
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65122
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Cell Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Inst Life Sci, Natl Key Lab Prot Engn & Plant Gene Engn, Beijing 100871, Peoples R China
3.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Hepatobiliary Surg 1, Beijing 100142, Peoples R China
4.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Pathol, Beijing 100142, Peoples R China
5.Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China

Recommended Citation:
Xu, Xiao-Lan,Xing, Bao-Cai,Han, Hai-Bo,et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient′s primary and recurrent tumor[J]. CARCINOGENESIS,2010,31(2):167-174.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Xu, Xiao-Lan]'s Articles
[Xing, Bao-Cai]'s Articles
[Han, Hai-Bo]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Xu, Xiao-Lan]‘s Articles
[Xing, Bao-Cai]‘s Articles
[Han, Hai-Bo]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace